Last updated: February 20, 2026
Focalin, the brand name for dexmethylphenidate, is a medication primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD). The drug is manufactured by multiple pharmaceutical companies under patent and licensing agreements. The primary suppliers and manufacturers are multinational corporations with authorized production facilities across North America, Europe, and Asia.
Key Manufacturers and Suppliers
| Company Name |
Location |
Product Description |
Market Authorization Status |
Notable Certifications |
| Novartis AG |
Basel, Switzerland |
Focalin and Focalin XR |
Approved in U.S., EU, and other markets |
Good Manufacturing Practice (GMP) |
| Teva Pharmaceutical Industries |
Petah Tikva, Israel |
Dexmethylphenidate Tablets |
Approved in U.S., Canada, and select markets |
FDA approved; international licenses |
| Sandoz (Novartis division) |
Holzkirchen, Germany |
Generic dexmethylphenidate |
Approved in multiple jurisdictions |
GMP, Certificates of Suitability (CEP) |
| Sutarn Pharmaceutical Ltd. |
India |
Dexmethylphenidate Tablets |
Registered with local health authorities |
WHO Good Manufacturing Practices (GMP) |
| Zhejiang Huahai Pharmaceutical |
China |
Dexmethylphenidate Generate |
Approved in Chinese market |
Chinese SFDA approval |
Patent and Licensing Landscape
- Patent Status: The original patent for Focalin by Novartis expired in various jurisdictions between 2015 and 2017, prompting generic manufacturers to produce off-patent versions.
- Licensing Agreements: Novartis controls manufacturing licenses for Focalin through licensing deals with generic companies. These agreements specify manufacturing standards, distribution rights, and geographic coverage.
Generic Supply Chain
- Manufacturers: Several companies, especially those in India and China, produce generic dexmethylphenidate under local regulatory approval.
- Regulatory Approvals: Generics are approved through individual agencies like the FDA (U.S.), EMA (Europe), and SFDA (China), adhering to local GMP standards.
- Market Share: In the U.S., Teva and Sandoz hold significant market share in generic Focalin sales, competing with newer entrants.
Supply Risks and Considerations
- Manufacturing Disruptions: Geopolitical tensions, supply chain issues, or regulatory actions in key manufacturing countries can impact availability.
- Quality Assurance: Suppliers must comply with strict GMP standards and hold certifications such as CE (Europe) and FDA approval (U.S.).
- Pricing Dynamics: Patent expirations led to increased competition, reducing prices for generic dexmethylphenidate.
Summary
Major suppliers for Focalin include Novartis (patented version), Teva, Sandoz, and multiple regional producers. The supply ecosystem has diversified post-patent expiration, increasing generic availability globally. Key countries producing Focalin or its generics include Switzerland, Israel, Germany, India, and China, with approval from respective health authorities.
Key Takeaways
- Novartis is the patent holder and primary brand producer for Focalin.
- Multiple generic manufacturers operate globally, especially in India and China.
- Patent expirations have increased generic supply, reducing prices.
- Supply chain risks include geopolitical factors and regulatory compliance challenges.
- Regulatory approvals vary by country, influencing manufacturing and distribution.
FAQs
1. Who are the main patent holders for Focalin?
Novartis holds the patent rights for Focalin in most regions; patent expiration has allowed generics to enter the market.
2. Which companies manufacture generic dexmethylphenidate?
Teva, Sandoz, and regional pharmaceutical firms in India (e.g., Sutarn Pharmaceutical) and China (e.g., Zhejiang Huahai).
3. Are there regional differences in manufacturing standards?
Yes. U.S. and European companies follow strict GMP protocols, while approvals in other countries vary by local standards.
4. How does patent expiration affect the supply of Focalin?
Patent expiration led to increased manufacturing of generics, expanding supply options and reducing prices.
5. What are the main supply risks associated with Focalin?
Disruptions can stem from geopolitical issues, regulatory changes, or manufacturing issues at key production sites.
References
- Novartis. (2022). Annual Report 2022. https://www.novartis.com
- FDA Green Book. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
- European Medicines Agency. (2023). Scientific Lifecycle Management. https://www.ema.europa.eu
- Sandoz. (2022). Corporate Overview. https://www.sandoz.com
- China Food and Drug Administration. (2023). Approved Drugs Database.
